Nicole C Schmitt1,2, Brandi R Page3. 1. a Office of the Clinical Director , National Institute on Deafness and Other Communication Disorders, National Institutes of Health , Bethesda , MD , USA. 2. b Department of Otolaryngology - Head and Neck Surgery , Johns Hopkins University , Baltimore , MD , USA , and. 3. c Department of Radiation Oncology and Molecular Sciences , Johns Hopkins University , Baltimore , MD , USA.
Abstract
OBJECTIVE: Review of the literature regarding hearing loss in patients with head and neck cancer treated with chemoradiation. DESIGN: Studies in the literature are reviewed that pertain to hearing loss sustained in head and neck cancer patients receiving cisplatin-based chemoradiation. Personal observations noted while treating these patients are also detailed. STUDY SAMPLE: PubMed was searched for pertinent articles regarding hearing loss in head and neck cancer patients receiving cisplatin chemotherapy and/or radiation. RESULTS: Studies on the incidence and severity of hearing loss in head and neck cancer patients are limited, but those studies suggest that the risk of hearing loss is greater with higher-dose regimens. CONCLUSIONS: Newer cisplatin chemotherapy regimens using lower, weekly doses may be associated with a lower incidence and severity of hearing loss; however, large prospective studies are needed. Such information will be paramount to effective pre-treatment counselling of head and neck cancer patients.
OBJECTIVE: Review of the literature regarding hearing loss in patients with head and neck cancer treated with chemoradiation. DESIGN: Studies in the literature are reviewed that pertain to hearing loss sustained in head and neck cancerpatients receiving cisplatin-based chemoradiation. Personal observations noted while treating these patients are also detailed. STUDY SAMPLE: PubMed was searched for pertinent articles regarding hearing loss in head and neck cancerpatients receiving cisplatin chemotherapy and/or radiation. RESULTS: Studies on the incidence and severity of hearing loss in head and neck cancerpatients are limited, but those studies suggest that the risk of hearing loss is greater with higher-dose regimens. CONCLUSIONS: Newer cisplatin chemotherapy regimens using lower, weekly doses may be associated with a lower incidence and severity of hearing loss; however, large prospective studies are needed. Such information will be paramount to effective pre-treatment counselling of head and neck cancerpatients.
Entities:
Keywords:
Conditions/pathology/disorders; adult or general hearing screening; demographics/epidemiology; hearing conservation/hearing loss prevention
Authors: Niranjan Bhandare; Patrick J Antonelli; Christopher G Morris; Robert S Malayapa; William M Mendenhall Journal: Int J Radiat Oncol Biol Phys Date: 2007-02-01 Impact factor: 7.038
Authors: Pedro Nazareth Aguiar; Hakaru Tadokoro; Gislaine Fernandes da Silva; Mayndra Mychelle Landgraf; Carmelia Maria Noia Barreto; Bruno Andraus Filardi; Gilberto de Lima Lopes; Pedro Oliveira; Ramon Andrade de Mello Journal: Future Oncol Date: 2016-08-23 Impact factor: 3.404
Authors: Charlotte L Zuur; Yvonne J Simis; Pauline E Lansdaal; Augustinus A Hart; Jan H Schornagel; Wouter A Dreschler; Coen R Rasch; Alfons J Balm Journal: J Clin Oncol Date: 2007-08-20 Impact factor: 44.544
Authors: Chiaho Hua; Johnnie K Bass; Raja Khan; Larry E Kun; Thomas E Merchant Journal: Int J Radiat Oncol Biol Phys Date: 2008-04-18 Impact factor: 7.038
Authors: Lori Zitelli; Catherine Palmer; Elizabeth Mamula; Jonas Johnson; Grant Rauterkus; Marci L Nilsen Journal: J Cancer Surviv Date: 2022-03-29 Impact factor: 4.442
Authors: Katharine Fernandez; Katie K Spielbauer; Aaron Rusheen; Lizhen Wang; Tiffany G Baker; Stephen Eyles; Lisa L Cunningham Journal: Hear Res Date: 2020-02-06 Impact factor: 3.208
Authors: Christiane Matuschek; Jan Haussmann; Edwin Bölke; Stephan Gripp; Patrick J Schuler; Bálint Tamaskovics; Peter Arne Gerber; Freddy-Joel Djiepmo-Njanang; Kai Kammers; Christian Plettenberg; Bahar Anooshahr; Klaus Orth; Wilfried Budach Journal: Radiat Oncol Date: 2018-10-04 Impact factor: 3.481